BioSpace News Archive

Strategic investment signals positive response of healthcare community to Theranica’s new approach to migraine management

Global digital therapeutics innovator DarioHealth Corp. reported record financial and operational results for the first quarter ended March 31, 2019.

Leading Third-Party Certification Provider Expands on FDA Effort to Address Questionable Ingredients Sold as Dietary Supplements

The lines between the physical and digital worlds are becoming increasingly blurred. Traditional markets are being redefined, customer expectations are constantly evolving, and the very way daily tasks are conducted are being rapidly transformed.

Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA® (ramucirumab injection, 10 mg/mL solution), as a single agent, for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha-fetoprotein (AFP) of ≥400 ng/mL and have been treated with sorafenib.

ITT Inc. Chief Financial Officer Thomas Scalera will present at the Goldman Sachs Industrials & Materials Conference 2019 in New York City on Thursday, May 16.

Serving Texas women since 1999, Superior HealthPlan is proud to recognize National Women’s Health Week, May 12–18.

Anixa Biosciences, Inc. announced that its Cchek™ Prostate Cancer Confirmation test successfully passed all required initial analytical verification studies en route to commercialization and implementation in the ResearchDx facility.

Selvita announced that the company will present at the UBS Global Healthcare Conference, taking place on May 20-22 in New York.

BiondVax Pharmaceuticals Ltd., developer of the M-001 universal influenza vaccine candidate, reported it will present this week at the 18th MIXiii-BIOMED Conference and Exhibition in Tel Aviv, Israel.